Jun 2026 (Q2 FY26) — Aug 11, 2026
Imunon Q2 FY26 — Ovation 3 Enrollment Exceeds Expectations and Continued Clinical Validation
Read the full callImunon (IMNN) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Imunon earnings: last reported Tue, 11 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -2.8 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$1.06 +1.92% · +$0.02
Performance −79.2% 1Y
1Y: $5.1 on 14 Oct 2025 → $1.06. High $5.1 (14 Oct 2025), low $1.04 (14 Oct 2026).
- Previous close
- $1.04
- 52-week range
- $1.04 – $5.1
- One year
- −77.92%
Overview
- Symbol
- IMNN
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Imunon earnings calls (IMNN)
Financials
What the filings say
Net profit, year on year: −3% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating profit | -5 | -4 | -4 | -3 | -3 | -4 | -4 | -3 |
| Other income | 0 | 0 | — | 0 | 0 | 0 | — | -0 |
| Interest | — | — | — | — | — | — | — | 0 |
| Net profit | -5 | -4 | -4 | -3 | -3 | -4 | -4 | -3 |
| EPS ($ per share) | -3.76 | — | -3.15 | -2.15 | -1.16 | — | -0.84 | -0.54 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 428 |
| Reserves | -274 | -291 | -312 | -333 | -369 | -388 | -407 | -421 |
| Total liabilities | 26 | 24 | 19 | 18 | 15 | 9 | 5 | 5 |
| Fixed assets | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Investments | 14 | 8 | — | 30 | 21 | 10 | — | — |
| Total assets | 47 | 38 | 38 | 74 | 44 | 22 | 10 | 12 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -7 | -20 | -16 | -16 | -23 | -19 | -19 | -14 |
| Cash from investing | -2 | 6 | 8 | -30 | 8 | 11 | 10 | -0 |
| Cash from financing | 11 | 8 | 18 | 55 | 7 | -4 | 9 | 17 |
| Net cash flow | 2 | -6 | 10 | 8 | -8 | -12 | 0 | 3 |
| Capital expenditure | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Free cash flow | -7 | -21 | -16 | -17 | -23 | -19 | -19 | -14 |
Insider filings
53 filings between May 22, 2026 and Oct 9, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$38.2K
6 sales by 1 insider
Compensation
not trading decisions- 47
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Eylward Susan | — | $38.2K | Aug 31, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 9, 2026 | Tardugno Michael H Executive Chairman of Board | Award | 7,800 | $8.4K |
| Oct 9, 2026 | Faller Douglas Vincent Chief Medical Officer | Award | 1,249 | $1.3K |
| Oct 9, 2026 | Lindborg Stacy President and CEO | Award | 2,977 | $3.2K |
| Sep 25, 2026 | Faller Douglas Vincent Chief Medical Officer | Award | 4,390 | $6.2K |
| Sep 25, 2026 | Lindborg Stacy President and CEO | Award | 6,697 | $9.4K |
| Sep 25, 2026 | Tardugno Michael H Executive Chairman of Board | Award | 7,169 | $10.1K |
| Sep 11, 2026 | Tardugno Michael H Executive Chairman of Board | Award | 5,824 | $8.6K |
| Sep 11, 2026 | Lindborg Stacy President and CEO | Award | 5,504 | $8.1K |
| Sep 11, 2026 | Faller Douglas Vincent Chief Medical Officer | Award | 4,211 | $6.2K |
| Aug 31, 2026 | Eylward Susan General Counsel and Corp Sec | Sale | 2,525 | $3.9K |
| Aug 28, 2026 | Eylward Susan General Counsel and Corp Sec | Award | 2,525 | $4.0K |
| Aug 28, 2026 | Faller Douglas Vincent Chief Medical Officer | Award | 3,626 | $5.8K |
| Aug 28, 2026 | Lindborg Stacy President and CEO | Award | 6,822 | $10.9K |
| Aug 28, 2026 | Tardugno Michael H Executive Chairman of Board | Award | 7,371 | $11.8K |
| Aug 17, 2026 | Eylward Susan General Counsel and Corp Sec | Sale | 2,449 | $4.0K |
| Aug 14, 2026 | Faller Douglas Vincent Chief Medical Officer | Award | 3,516 | $5.8K |
| Aug 14, 2026 | Lindborg Stacy President and CEO | Award | 6,615 | $10.9K |
| Aug 14, 2026 | Tardugno Michael H Executive Chairman of Board | Award | 7,147 | $11.8K |
| Aug 14, 2026 | Eylward Susan General Counsel and Corp Sec | Award | 2,449 | $4.0K |
| Aug 3, 2026 | Eylward Susan General Counsel and Corp Sec | Sale | 2,541 | $4.0K |
| Jul 31, 2026 | Lindborg Stacy President and CEO | Award | 5,010 | $8.0K |
| Jul 31, 2026 | Tardugno Michael H Executive Chairman of Board | Award | 6,358 | $10.1K |
| Jul 31, 2026 | Eylward Susan General Counsel and Corp Sec | Award | 2,541 | $4.0K |
| Jul 31, 2026 | Faller Douglas Vincent Chief Medical Officer | Award | 3,649 | $5.8K |
| Jul 31, 2026 | Braun Donald P Director | Award | 6,180 | $9.8K |
| Jul 31, 2026 | Fritz Frederick J. Director | Award | 6,934 | $11.0K |
| Jul 31, 2026 | Dentzer James E Director | Award | 6,934 | $11.0K |
| Jul 31, 2026 | Pellizzari Christine A Director | Award | 6,934 | $11.0K |
| Jul 20, 2026 | Eylward Susan General Counsel and Corp Sec | Sale | 2,150 | $3.8K |
| Jul 17, 2026 | Lindborg Stacy President and CEO | Award | 4,907 | $9.0K |
| Jul 17, 2026 | Faller Douglas Vincent Chief Medical Officer | Award | 3,082 | $5.6K |
| Jul 17, 2026 | Eylward Susan General Counsel and Corp Sec | Award | 2,150 | $3.9K |
| Jul 17, 2026 | Tardugno Michael H Executive Chairman of Board | Award | 4,603 | $8.4K |
| Jul 6, 2026 | Eylward Susan General Counsel and Corp Sec | Sale | 920 | $1.7K |
| Jul 2, 2026 | Tardugno Michael H Executive Chairman of Board | Award | 4,410 | $8.4K |
| Jul 2, 2026 | Lindborg Stacy President and CEO | Award | 2,534 | $4.8K |
| Jul 2, 2026 | Faller Douglas Vincent Chief Medical Officer | Award | 1,308 | $2.5K |
| Jul 2, 2026 | Eylward Susan General Counsel and Corp Sec | Award | 920 | $1.8K |
| Jun 29, 2026 | Eylward Susan General Counsel and Corp Sec | Sale | 11,800 | $20.7K |
| Jun 25, 2026 | Faller Douglas Vincent Chief Medical Officer | Award | 21,896 | $37.7K |
| Jun 25, 2026 | Eylward Susan General Counsel and Corp Sec | Award | 14,696 | $25.3K |
| Jun 25, 2026 | Tardugno Michael H Executive Chairman of Board | Award | 42,519 | $73.1K |
| Jun 25, 2026 | Lindborg Stacy President and CEO | Award | 67,150 | $115.5K |
| Jun 18, 2026 | Tardugno Michael H Executive Chairman of Board | Award | 4,629 | $8.4K |
| Jun 18, 2026 | Lindborg Stacy President and CEO | Award | 1,803 | $3.3K |
| Jun 5, 2026 | Tardugno Michael H Executive Chairman of Board | Award | 4,089 | $8.4K |
| Jun 5, 2026 | Lindborg Stacy President and CEO | Award | 1,593 | $3.3K |
| May 22, 2026 | Lindborg Stacy President and CEO | Award | 1,491 | $3.3K |
| May 22, 2026 | Tardugno Michael H Executive Chairman of Board | Award | 3,484 | $7.7K |
| May 22, 2026 | Pellizzari Christine A Director | Award | 5,557 | $12.2K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Imunon, Inc.
Free account. Everything above stays public.
Write why you follow Imunon, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading